论文部分内容阅读
目的探讨不同方案在骨髓增生异常综合征中的疗效。方法 2008年1月至2010年6月收治的骨髓增生异常综合征45例,分为CSA联合沙利度胺治疗组23例,单纯CSA治疗的对照组22例,观察两组临床疗效。结果 CSA联合沙利度胺治疗组总有效率78.26%,明显优于单纯CSA治疗的对照组总有效率45.45%,两组总有效率比较差异有统计学意义(P<0.01)。结论 CSA联合沙利度胺治疗骨髓增生异常综合征,临床效果显著提高,毒副作用少,患者耐受性好,应用方便等优点。
Objective To investigate the efficacy of different regimens in myelodysplastic syndromes. Methods From January 2008 to June 2010, 45 cases of myelodysplastic syndromes were divided into CSA plus thalidomide group (n = 23) and CSA alone group (n = 22). The clinical efficacy was observed. Results The total effective rate was 78.26% in CSA combined with thalidomide group and 45.45% in control group with CSA alone. There was significant difference between the two groups in total effective rate (P <0.01). Conclusion CSA combined with thalidomide in the treatment of myelodysplastic syndrome, clinical effect was significantly improved, fewer side effects, patient tolerance, ease of use and so on.